Background: Preeclampsia a chief clinical scenario in obstetric medicine, having highly morbid and grave sequalae particularly
if rapidly progressive and left unmanaged. The complexity of immune system components involvement is integrated in the
preeclampsia pathology as immune based pathology is one of the cornerstone theories for preeclampsia development that have
raised the issue that immune dysfunction affection is an issue that could be investigated in recent research efforts to reveal any
immunological biomarker that could be implemented as a predictability tool for preeclampsia development and severity.
Aim: To investigate the possible usage of immune biomarkers in prediction of preeclampsia..
Methodology: The current study was conducted at Departments of Obstetrics & Gynecology and Clinical Pathology, Tanta
University Hospitals. A prospective clinical research trial that involved cases having an ongoing gestation below 16 gestational
weeks of with maternal age range of 18 to 40 years old were recruited in the current research study. During the study period, a total
of 200 research study subjects. Peripheral blood was collected between 5th and 16th gestational weeks calculating the gestational
age based on the last menstrual period and crown-rump length using a first trimester sonographic scan cases were clinically and
investigationally followed till time of delivery and clinical research data was collected and tabulated for analysis the following was
conducted on collected blood samples.
Results: The comparative statistical analysis women with and without pre-eclampsia regarding Serum levels (pg/ml) of
cytokines and chemokines in which there was no statistical significant difference between both research groups as regards EGF,
EOTAXING-CSF,GM-CSF ,IFN ALPHA 2,IFN-GAMMA , IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL17-A, IL-1RA, IL-1 alpha, IL-1 beta,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IP-10, MIP-1 beta, TNF- alpha, TNF-beta, VEGF (p values=0.812, 0.315, 0.712, 0.635, 0.511, 0.865,
0.829, 0.873, 0.603, 0.807, 0.865, 0.512, 0.925, 0.812, 0.512,0.310,0.423 ,0.478, 0.829, 0.903 ,0.865, 0.314, 0.885, 0.489,0.958,0.288
consecutively) however there was highly statistically significantly higher levels of IL-8 among the preeclampsia research group, and
statically significantly higher levels of MCP-1 among no preeclampsia research group (p value= 0.012), whereas there was statically
significantly higher levels of MIP-1 alpha among preeclampsia research group (p value= 0.032).
Conclusion: The current study findings denote that there is a possible clinical value in using immune biomarkers in preeclampsia
screening, however future research efforts are required to verify the current study results in order to elucidate more clearly the most
useful immune cell ratios and inflammatory mediators that could be clinically applicable and useful with the highest sensitivity in
order to upgrade the management protocols of preeclampsia.